HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 173 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $13,984,000 | -65.6% | 488,638 | -67.8% | 0.04% | -67.2% |
| Q2 2020 | $40,688,000 | +42.8% | 1,517,627 | -4.2% | 0.13% | +24.3% |
| Q1 2020 | $28,490,000 | -1.8% | 1,583,675 | -3.2% | 0.10% | +30.4% |
| Q4 2019 | $29,015,000 | +14.2% | 1,636,475 | -0.1% | 0.08% | +9.7% |
| Q3 2019 | $25,397,000 | -12.9% | 1,637,475 | -3.5% | 0.07% | -8.9% |
| Q2 2019 | $29,142,000 | -15.0% | 1,696,275 | -20.3% | 0.08% | -15.1% |
| Q1 2019 | $34,265,000 | +9.9% | 2,128,275 | -0.1% | 0.09% | +3.3% |
| Q4 2018 | $31,173,000 | -21.1% | 2,130,775 | -1.9% | 0.09% | -9.1% |
| Q3 2018 | $39,485,000 | +10.2% | 2,173,089 | +2.3% | 0.10% | +12.5% |
| Q2 2018 | $35,841,000 | -39.1% | 2,124,563 | -29.3% | 0.09% | -40.1% |
| Q1 2018 | $58,863,000 | -35.9% | 3,004,753 | -33.7% | 0.15% | -31.9% |
| Q4 2017 | $91,800,000 | -18.0% | 4,531,081 | -29.7% | 0.22% | -13.6% |
| Q3 2017 | $111,949,000 | +18.1% | 6,444,981 | -12.8% | 0.25% | +10.1% |
| Q2 2017 | $94,795,000 | -1.1% | 7,394,315 | 0.0% | 0.23% | -3.8% |
| Q1 2017 | $95,830,000 | +26.2% | 7,394,315 | -3.8% | 0.24% | +22.3% |
| Q4 2016 | $75,953,000 | -15.0% | 7,687,515 | +3.9% | 0.19% | -14.6% |
| Q3 2016 | $89,338,000 | +45.8% | 7,395,500 | +4.1% | 0.23% | +44.9% |
| Q2 2016 | $61,282,000 | -2.9% | 7,101,000 | +6.6% | 0.16% | -2.5% |
| Q1 2016 | $63,105,000 | -15.4% | 6,663,700 | +54.8% | 0.16% | -14.4% |
| Q4 2015 | $74,621,000 | +36.9% | 4,305,900 | +6.1% | 0.19% | +36.5% |
| Q3 2015 | $54,506,000 | -42.0% | 4,058,500 | -2.5% | 0.14% | -38.8% |
| Q2 2015 | $93,978,000 | +71.6% | 4,162,000 | +8.6% | 0.22% | +72.3% |
| Q1 2015 | $54,750,000 | +42.2% | 3,834,050 | -3.9% | 0.13% | +38.3% |
| Q4 2014 | $38,508,000 | +16.2% | 3,990,480 | +9.6% | 0.09% | +14.6% |
| Q3 2014 | $33,128,000 | +20.0% | 3,640,480 | +30.2% | 0.08% | +22.4% |
| Q2 2014 | $27,615,000 | +51.7% | 2,795,080 | +94.9% | 0.07% | +39.6% |
| Q1 2014 | $18,209,000 | -6.2% | 1,433,780 | +10.8% | 0.05% | -9.4% |
| Q4 2013 | $19,406,000 | – | 1,294,580 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |